Browsing articles in "Cognitive Disorders"

 
Blood Test Predicts Which People With Amyloid Are Likely to Decline Cognitively
March 1, 2023   

The pathology of Alzheimer’s disease (AD) begins with a prolonged phase of beta-amyloid accumulation without symptoms. The duration of this phase varies widely depending on the individual. A recent prospective population-based study examined data from 2 prospective longitudinal cohorts...
 Continue reading (Members only)
'Convincing Evidence' Hearing Aids Reduce Dementia Risk
December 20, 2022   

With no truly effective treatment for dementia yet available, there is increased interest in lifestyle factors that may delay or prevent the onset of dementia. Previous studies have shown that hearing loss is associated with increased risk of dementia and cognitive decline. There are 3 main hypotheses for this association...
 Continue reading
Association Between Consumption of Ultraprocessed Foods and Cognitive Decline
December 16, 2022   

In a recent cohort study, the relationship benzodiazepines versus alternative medications prescribed for sleep disorders and increased risk of drug overdose in adolescents was examined. The study included participants diagnosed with a sleeping disorder between the age of 10 to 29 years of age between January...
 Continue reading (Members only)
FDA Authorizes Marketing for New Test to Improve Diagnosis of Alzheimer’s Disease
May 9, 2022   

The U.S. Food and Drug Administration (FDA) approved marketing authorizationnfor anst in vitro diagnostic test for the early detection of amyloid plaques, one of the pathological hallmarks associated with Alzheimer's adises. The test is the first FDA-authorized in vitro diagnostic test in the U.S. to aid in the assessment of Alzheimer’s disease and other causes of cognitive decline...
 Continue reading (Members only)
Impact of Neuropsychiatric Symptoms in Alzheimer’s Disease
March 4, 2022   

Neuropsychiatric symptoms, including depression, apathy, and anxiety, are common among individuals with Alzheimer’s dementia. It is not yet clear the relationship among NPS, cognitive symptoms, and Alzheimer’s dementia neuropathology (which includes amyloid beta deposits, neurofibrillary tangles composed of hyperphosphorylated tau, and neurodegeneration). In this article...
 Continue reading
5-HT4-Receptor Agonists May Boost Cognitive Impairments Associated With Psychiatric Disorders
October 25, 2021   

Many psychiatric disorders include symptoms of cognitive impairment, which has been challenging to treat. Mounting evidence from animal studies suggest that the 5-HT4 receptor could be a promising potential treatment target for cognitive impairment because...
 Continue reading (Members only)
ADHD and Alzheimer’s Disease Across Generations
September 25, 2021   

Due to previous conflicting results regarding the association between attention-deficit hyperactivity disorder (ADHD) and Alzheimer’s disease (AD), a recent nationwide cohort study evaluated their link across generations. Index persons (N=2,132,929) born in Sweden were linked to their biological relatives: 4,246,182 index person-parent pairs....
 Continue reading (Members only)
Histamine 3 Receptor Inverse Agonist For Cognitive Disorders
February 26, 2021   

istamine H3 receptors, found throughout the cortex and hippocampus, have been hypothesized to be involved with cognition, learning, and memory. Several preclinical animal model studies have shown that H3 receptor antagonists/inverse agonists may have procognitive effects; however...
 Continue reading (Members only)
Systolic Orthostatic Hypotension Tied to Dementia Risk
August 21, 2020   

A recent study examined whether orthostatic hypotension and visit-to-visit blood pressure postural changes variability are associated with incident dementia. The study involved 2,131 people aged 73 years old on average. Repeatedly over a period of five years, researchers A recent study examined whether orthostatic hypotension and visit-to-visit blood pressure postural changes variability are associated with incident dementia. The study involved 2,131 people aged 73 years old on average. Over a period of five years, researchers...
 Continue reading (Members only)
Biogen Submits Application for US Approval for Alzheimer Drug
July 27, 2020   

Biogen completed the submission of a Biologics License Application for its monoclonal antibody aducanumab to the US Food and Drug Administration for the treatment of Alzheimer’s disease...
 Continue reading (Members only)
123
Top of Page